Roche Unveils AI-Powered Chest Pain Triage Algorithm to Streamline Emergency Cardiac Care

Roche Unveils AI-Powered Chest Pain Triage Algorithm to Streamline Emergency Cardiac Care

(IN BRIEF) Roche has launched a CE-marked Chest Pain Triage algorithm developed with Universitätsklinikum Heidelberg to improve emergency diagnosis of chest pain. Integrated into the navify® Algorithm Suite, the tool uses high-sensitivity cardiac troponin testing and ESC guidelines to support rapid and reliable triage decisions. It automatically selects diagnostic pathways to help rule in or rule out heart attacks, reducing patient stay times and easing ED pressure. Now available in Europe, Asia, and the Middle East, it exemplifies Roche’s mission to enhance cardiovascular care with data-driven tools.

(PRESS RELEASE) BASEL, 24-Apr-2025 — /EuropaWire/ — Roche has introduced a groundbreaking Chest Pain Triage algorithm, developed in partnership with Universitätsklinikum Heidelberg, as part of the navify® Algorithm Suite. This CE-marked in vitro diagnostic (IVD) medical device is designed to significantly improve the accuracy and speed of triaging chest pain cases in emergency departments (EDs), where swift differentiation between cardiac and non-cardiac causes is crucial.

Leveraging high-sensitivity cardiac troponin T assays and incorporating European Society of Cardiology (ESC) guidelines, the algorithm provides clinicians with precise Rule-In, Rule-Out, or Observe recommendations. It automatically selects the appropriate diagnostic pathway based on the timing of sample collection, reducing Emergency Department stay times by more than three hours in many cases.

This innovative tool simplifies decision-making, cuts down on unnecessary admissions, and accelerates treatment for acute coronary syndrome (ACS) cases. Fully integrated with lab information systems (LIS) and electronic health records (EHR), it streamlines workflow while enhancing documentation and clinical confidence.

Matt Sause, CEO of Roche Diagnostics, said, “Our Chest Pain Triage algorithm helps tackle one of the major bottlenecks in emergency care: the timely and accurate assessment of chest pain. It supports clinicians in identifying true cardiac emergencies while reducing the burden on overstretched departments.”

Now available in Europe, Asia, and the Middle East, with U.S. availability forthcoming, the algorithm is part of Roche’s broader cardiometabolic portfolio aimed at improving early detection and care for cardiovascular disease—responsible for one-third of all deaths worldwide.

This latest addition to Roche’s navify platform reflects the company’s commitment to digital innovation and precision diagnostics. The navify portfolio comprises over 30 digital solutions designed to support lab, hospital, and patient care worldwide through secure, GDPR- and HIPAA-compliant technologies.

About navify
The navify portfolio from Roche includes more than 30 digital solutions for labs, hospitals and patients worldwide. navify solutions connect the healthcare community with a robust digital infrastructure to integrate data efficiently and to accelerate clinician access to innovations as well as operational and medical insights. This work includes collaborating with other innovative companies such as Fortinet in cybersecurity services. The navify platform is designed to deliver security at every step of the data analytical process. All data is encrypted at rest and in transit. The solution is operated in compliance with applicable laws and regulations in the USA with HIPAA  (Health Insurance Portability and Accountability) as well as with GDPR (General Data Protection Regulation) regulations in Europe.

Healthcare professionals can visit navify Marketplace to browse and request a growing number of next generation digital solutions from Roche and other companies — all designed to drive operational and clinical excellence, built on the foundational pillars of digital trust. More information is also available at navify.com.

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.

For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit www.roche.com.

All trademarks used or mentioned in this release are protected by law.

* Availability will depend on the specific market and country in some cases. Please consult a local Roche representative for the availability of the chest pain algorithm in your market

References
[1] European Union: EUR-Lex. Chest Pain Triage algorithm registration [Internet: accesses March 24, 2025] Chest Pain Triage algorithm is an in-vitro diagnostic (IVD) medical device CE-marked (NB 0123)  under the requirements laid out in the IVD regulation (EU) 2017/746 (IVDR).
[2] Saloni D et al. Cardiovascular Diseases. [Internet: accessed March 24, 2025]. Available from: https://ourworldindata.org/cardiovascular-diseases?insight=cardiovascular-diseases-are-the-most-common-cause-of-death-worldwide#all-charts
[3] Yukselen Z, Majmundar V, Dasari M, Arun Kumar P, Singh Y. Chest Pain Risk Stratification in the Emergency Department: Current Perspectives. Open Access Emerg Med. 2024 Feb 4;16:29-43. doi: 10.2147/OAEM.S419657. PMID: 38343728; PMCID: PMC10853047
[4] Sartini M, et al. Overcrowding in Emergency Department: Causes, consequences, and solutions – a narrative review. Healthcare (Basel). 2022 Aug;10(9):1625)
[5] Anand A, et al. High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: A stepped-wedge cluster randomized controlled trial. Circulation. 2021 Jun;143(23):2214-2224)

Media Contacts:

Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com

SOURCE: ROCHE